Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cellsMartuza Sarwar(Lund University), Jenny L. Persson(Umeå University)OncotargetAugust 31, 201610.18632/oncotarget.11757Cited by 47SaveCiteExport RISWatch citationsRelated PapersCyclin A1 Modulates the Expression of Vascular Endothelial Growth Factor and Promotes Hormone-Dependent Growth and Angiogenesis of Breast Cancer|PLoS ONE|2013|32